Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:CLGN NASDAQ:IRIX NASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.76-0.7%$2.72$2.15▼$22.59$20.73M-0.45214,508 shs21,314 shsCLGNCollPlant Biotechnologies$2.33-3.7%$1.91$1.31▼$5.45$30.77M1.4564,108 shs20,491 shsIRIXIRIDEX$1.28-3.0%$1.06$0.78▼$2.14$21.49M0.62191,987 shs49,855 shsPOAIPredictive Oncology$0.76-3.4%$0.86$0.55▼$3.06$8.07M1.18218,560 shs127,764 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+0.18%-9.06%+7.81%+21.59%-87.16%CLGNCollPlant Biotechnologies-3.72%+0.87%+64.08%+8.88%-45.56%IRIXIRIDEX-3.03%-9.22%+40.63%+7.56%-36.32%POAIPredictive Oncology-3.42%-4.68%-8.67%-30.73%-32.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.1301 of 5 stars3.53.00.00.00.61.70.6CLGNCollPlant Biotechnologies2.1216 of 5 stars3.73.00.00.00.00.00.6IRIXIRIDEX0.4788 of 5 stars0.04.00.00.00.61.70.0POAIPredictive Oncology1.3132 of 5 stars3.03.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 3.00Buy$22.83727.29% UpsideCLGNCollPlant Biotechnologies 3.33Buy$11.50393.56% UpsideIRIXIRIDEX 0.00N/AN/AN/APOAIPredictive Oncology 2.00Hold$3.00293.70% UpsideCurrent Analyst Ratings BreakdownLatest POAI, CLGN, ALUR, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.64N/AN/A($30.08) per share-0.09CLGNCollPlant Biotechnologies$510K58.11N/AN/A$1.18 per share1.97IRIXIRIDEX$48.80M0.44N/AN/A$0.13 per share9.85POAIPredictive Oncology$1.62M4.81N/AN/A($0.03) per share-25.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$26.15M-$12.50N/AN/AN/A-86.05%N/A-41.49%8/12/2025 (Estimated)CLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%8/19/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/12/2025 (Estimated)POAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)Latest POAI, CLGN, ALUR, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CLGNCollPlant Biotechnologies$0.29N/AN/AN/A$8.91 millionN/A8/12/2025Q2 2025ALURAllurion Technologies-$0.65N/AN/AN/A$6.20 millionN/A8/12/2025Q2 2025POAIPredictive Oncology-$0.09N/AN/AN/AN/AN/A6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/14/2025Q1 2025ALURAllurion Technologies-$1.53$0.43+$1.96$0.20$5.50 million$5.58 million5/14/2025Q1 2025POAIPredictive Oncology-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ACLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.091.88CLGNCollPlant BiotechnologiesN/A4.484.23IRIXIRIDEX4.281.951.27POAIPredictive OncologyN/A0.760.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%CLGNCollPlant Biotechnologies21.69%IRIXIRIDEX20.10%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%CLGNCollPlant Biotechnologies9.60%IRIXIRIDEX7.40%POAIPredictive Oncology3.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.46 million5.79 millionOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableIRIXIRIDEX12016.79 million15.55 millionOptionablePOAIPredictive Oncology3010.22 million9.87 millionNot OptionablePOAI, CLGN, ALUR, and IRIX HeadlinesRecent News About These CompaniesPredictive Oncology files to sell 1.92M shares of common stock for holdersJuly 21, 2025 | msn.comPredictive Oncology Planning ChemoFx Launch in Europe, US Amid Potential Nasdaq DelistingJuly 16, 2025 | precisionmedicineonline.comPPredictive Oncology Inc.: Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx and Pursuit of Other ...July 16, 2025 | finanznachrichten.dePredictive Oncology Inc. Secures $10 Million Securities Purchase Agreement to Support Growth Initiatives and ChemoFx ExpansionJuly 15, 2025 | quiverquant.comQPredictive Oncology stock falls after announcing $10M equity purchase deal - Investing.com UKJuly 10, 2025 | uk.investing.comPredictive Oncology Inc. Enters Standby Equity Purchase Agreement with Yorkville Advisors for Up to $10 Million in Funding - NasdaqJuly 10, 2025 | nasdaq.comPredictive Oncology secures $10 million equity purchase agreementJuly 10, 2025 | uk.investing.comPredictive Oncology Shares Slip After Signing $10M Equity Purchase AgreementJuly 8, 2025 | msn.comPredictive Oncology Inc. Enters Standby Equity Purchase Agreement with Yorkville Advisors for Up to $10 Million in FundingJuly 8, 2025 | quiverquant.comQPredictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and RepurposingJuly 8, 2025 | globenewswire.comPredictive Oncology Inc. (POAI) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.com6 Ways Predictive Maintenance Impacts Concrete Truck OpsJuly 2, 2025 | forconstructionpros.comFPredictive Discovery’s DFS for Bankan delivers good returnsJuly 2, 2025 | miningreview.comMAgenus, Noetik Partner to Discover Predictive Immuno-Oncology Biomarkers Using AI Foundation ModelJune 17, 2025 | precisionmedicineonline.comPPredictive Oncology Inc. Develops Exclusive 3D Organoid Models for Labcorp to Enhance Drug Discovery and Safety EvaluationJune 12, 2025 | quiverquant.comQPredictive Oncology Develops Functional 3D Organoid Models Exclusively for LabcorpJune 12, 2025 | globenewswire.comPredictive Oncology Inc.: Court Denies Renovaro Motion for an Expedited Trial in JulyMay 27, 2025 | finanznachrichten.deCourt Denies Renovaro Motion for an Expedited Trial in JulyMay 27, 2025 | globenewswire.comPredictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans BullishMay 23, 2025 | msn.comPredictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor SamplesMay 22, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOAI, CLGN, ALUR, and IRIX Company DescriptionsAllurion Technologies NYSE:ALUR$2.76 -0.02 (-0.72%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$2.77 +0.01 (+0.36%) As of 08/1/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.CollPlant Biotechnologies NASDAQ:CLGN$2.33 -0.09 (-3.72%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$2.31 -0.02 (-1.07%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.IRIDEX NASDAQ:IRIX$1.28 -0.04 (-3.03%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.26 -0.02 (-1.56%) As of 08/1/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Predictive Oncology NASDAQ:POAI$0.76 -0.03 (-3.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.75 -0.02 (-1.97%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
